Volume 16, Issue 3 (May & June 2025)                   BCN 2025, 16(3): 609-618 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Behruzi M, Ghorbanlou M, Shabani R, Rustamzadeh A, Alhagh Gorgich E, Seidkhani E, et al . Vismodegib Improved Therapy of Medulloblastoma by Targeting Sonic Hedgehog Signaling Pathway on DAOY Medulloblastoma Cell Line. BCN 2025; 16 (3) :609-618
URL: http://bcn.iums.ac.ir/article-1-2905-en.html
1- Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
2- Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran. & Department of Anatomical Sciences, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
3- Department of Anatomy, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
4- Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. & Reproductive Sciences and Technology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abstract:  
Introduction: Targeting smoothened (SMO) has been a remarkable strategy for treating sonic hedgehog (Shh)-dependent cancers, especially medulloblastoma. GDC-0449, also known as vismodegib, is a potent SMO inhibitor with mild toxicity and high affinity. Thus, this study aimed to investigate the anti-medulloblastoma efficacy of vismodegib in the DAOY medulloblastoma cell line. 
Methods: Human DAOY medulloblastoma cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM). 50, 80, 100, and 150 μM doses of vismodegib were used to treat cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), scratch, and trypan blue assays, as well as real-time polymerase chain reaction (RT-PCR) and immunofluorescence studies, were performed 24 and 48 h post-treatment. 
Results: The MTT and trypan blue assays showed a significant difference in viability between the control and treatment groups. The results of the scratch assay showed that in the control group, the cells were able to repair the lesion, while the scratch disintegrated at higher doses of vismodegib. The expression of SMO, Gli1, and MYCN genes, the main components of the SHH signalling pathway, was significantly reduced in the vismodegib-treated groups compared to the control group. Also, a notable increase in the activation of metastasis-promoting genes (Bax and p53) and a reduction in the activation of the metastasis-inhibiting gene (Bcl2) were observed.
Conclusion: The results of the current study confirm that vismodegib is a potent inhibitor of the Shh pathway and may be used in combination with new therapeutic methods to treat medulloblastoma.
Full-Text [PDF 2205 kb]   |   |   Full-Text (HTML)   
Type of Study: Original | Subject: Cellular and molecular Neuroscience
Received: 2024/03/17 | Accepted: 2024/04/11 | Published: 2025/05/29

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb